Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects
Rupali Bhardwaj (TU Delft - Applied Sciences)
Astrid van der Meer (TU Delft - Applied Sciences)
Satyen Das (TU Delft - Applied Sciences)
M de Bruin (TU Delft - Applied Sciences)
Jorge Gascon (TU Delft - Applied Sciences)
Bert Wolterbeek (TU Delft - Applied Sciences)
Antonia Denkova (TU Delft - Applied Sciences)
Pablo Serra Crespo (TU Delft - Applied Sciences)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
177Lu has sprung as a promising radionuclide for targeted therapy. The low soft tissue penetration of its β− emission results in very efficient energy deposition in small-size tumours. Because of this, 177Lu is used in the treatment of neuroendocrine tumours and is also clinically approved for prostate cancer therapy. In this work, we report a separation method that achieves the challenging separation of the physically and chemically identical nuclear isomers, 177mLu and 177Lu. The separation method combines the nuclear after-effects of the nuclear decay, the use of a very stable chemical complex and a chromatographic separation. Based on this separation concept, a new type of radionuclide generator has been devised, in which the parent and the daughter radionuclides are the same elements. The 177mLu/177Lu radionuclide generator provides a new production route for the therapeutic radionuclide 177Lu and can bring significant growth in the research and development of 177Lu based pharmaceuticals.
help_outline